10:19 AM EST - Aeterna Zentaris Inc. : Has entered into an exclusive option agreement to evaluate a preclinical potential COVID-19 vaccine developed at the Julius-Maximilians-University Wuerzburg, one of Germany’s leading research and teaching universities. The vaccine technology developed at the University uses a typhoid fever vaccine as a carrier strain and has the potential to be an orally active COVID-19 (SARS-CoV-2) live-attenuated bacterial vaccine. Aeterna Zentaris Inc.
shares T.AEZS are trading up $0.38 at $1.27.
